Here is a data-driven look at Natco Pharma Limited (NATCOPHARM), covering financial performance, valuation, and shareholding trends.
Natco Pharma Revenue Trend
Natco Pharma Limited reported revenue of ₹4,784 Cr in FY2025, a 15.9% increase from ₹4,127 Cr in FY2024.
Natco Pharma Limited has delivered a 19.2% revenue CAGR over 10 years — strong, sustained top-line expansion from ₹825 Cr to ₹4,784 Cr.
Natco Pharma Limited's ₹4,784 Cr revenue base puts it in the mid-sized bracket among pharmaceuticals companies in India.
Natco Pharma Limited has posted revenue growth for 3 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹4,784 Cr | +15.9% |
| FY2024 | ₹4,127 Cr | +46.8% |
| FY2023 | ₹2,812 Cr | +37.6% |
| FY2022 | ₹2,044 Cr | -5.2% |
| FY2021 | ₹2,156 Cr | — |
View Natco Pharma Limited's full 10-year revenue trend with CAGR analysis →
Natco Pharma Profitability
Natco Pharma Limited turned in a net profit of ₹1,883 Cr for FY2025. That's 35.7% better than the ₹1,388 Cr earned in FY2024.
The company squeezed out better margins in FY2025, with net margin at 39.4% versus 33.6% in FY2024.
Per-share earnings moved to ₹105.26 in FY2025 from ₹77.34 in FY2024.
Is Natco Pharma Undervalued
The P/E Ratio valuation pegs Natco Pharma Limited's fair value at ₹2,081, which is 122.7% upside from the current price.
Natco Pharma Limited shares are currently trading at ₹934.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹2,081 | 122.7% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Natco Pharma Limited with detailed assumptions →
Natco Pharma Shareholding Pattern
Promoters haven't moved — their 49.4% holding has been unchanged for 4 quarters.
Foreign investors held 17.4% of the company as of March 2026, up year-over-year from 15.5%.
DII ownership is at 5.5%, down from the 5.8% recorded a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 49.4% | 17.4% | 5.5% | 27.8% |
| Dec 2025 | 49.5% | 15.2% | 5.4% | 30.0% |
| Sep 2025 | 49.5% | 14.1% | 5.9% | 30.6% |
| Jun 2025 | 49.6% | 15.5% | 5.8% | 29.1% |
Track quarterly shareholding changes for Natco Pharma Limited →
Natco Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹86.31B (up 25.0% YoY from ₹69.06B).
Top categories: Other Assets (35.9%), Property, Plant & Equipment (30.8%), Receivables (14.4%).
Of the ₹86.31B in liabilities and equity, 88.2% is shareholder equity, 3.2% is interest-bearing debt, and 8.6% is operating liabilities. Over the year, debt is down 24.7% and equity is up 30.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 4.41B |
| Receivables | 12.47B |
| Inventories | 7.66B |
| Property, Plant & Equipment | 26.57B |
| Investments | 1.53B |
| Intangibles & Goodwill | 2.66B |
| Other Assets | 31.01B |
| Category | Value |
|---|---|
| Equity | 76.12B |
| Short-term Debt | 2.75B |
| Long-term Debt | 46.00M |
| Trade Payables | 2.75B |
| Other Liabilities | 4.64B |
Natco Pharma Key Takeaways
In summary, Natco Pharma Limited (NATCOPHARM) presents the following picture for fundamental analysts.
Revenue of ₹4,784 Cr in FY2025, up 15.9% year-over-year.
Long-term revenue has been compounding at 19.2% annually over 10 years.
The company is profitable, with a net margin of 39.4% and net income of ₹1,883 Cr.
The P/E Ratio model implies 122.7% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Natco Pharma Limited.